Healing & Recovery / side effects and safety / Last reviewed 2026-06-02

GHR Peptide-6 Side Effects: Safety Signals and Warnings

GHR Peptide-6 safety concerns are compound-specific. The main listed side effects are Limited safety data available, Possible local irritation at application site, and Potential appetite stimulation (shared with GHRP-6). The main warning signals are Not approved for clinical use in any country, Evidence base is limited and primarily from a single research group, and Relationship to GHRP-6 may carry similar endocrine side effects at systemic doses.

Read the full GHR Peptide-6 guide Browse answer pages

Direct Answer

Evidence for GHR Peptide-6 is too preliminary to support a research protocol with confidence. Published data is extremely limited, with no independent replication and no clinical trials. Of the Healing & Recovery compounds in this library, BPC-157 or thymosin beta-4 have substantially more preclinical evidence as starting points.

Evidence grade
Level D
Research status
Preclinical
Category
Healing & Recovery
Best for
No validated application at this stage

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

GHR Peptide-6 wound healing variant is a research compound. Not approved for clinical use. GHRP-6 and its analogs are classified as research chemicals in most jurisdictions and are banned by WADA.

Evidence Snapshot

Evidence gradeLevel D
Research statusPreclinical
Best supported outcomesChronic Wound Healing (Level D) and Burn Injury Recovery (Level D)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "GHR Peptide-6 Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/ghr-peptide-6-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.